2 results match your criteria: "Jiangxi Branch of the National Clinical Research Center for Ocular Disease[Affiliation]"

Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.

Ther Adv Drug Saf

October 2024

Xiamen University Affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, 401 Chengyi Build, Xiang-an Campus of Xiamen University, South Xiang-an Road, Xiamen, Fujian 361005, China.

Article Synopsis
  • - The study investigates common adverse events related to four prostaglandin medications used for glaucoma (latanoprost, bimatoprost, travoprost, and tafluprost) using the FDA's Adverse Event Reporting System (FAERS) database.
  • - It involves a detailed statistical analysis of adverse event data, revealing that eye disorders, particularly iris hyperpigmentation and corneal irritation, are significant issues associated with these drugs.
  • - The findings indicate that adverse events occur differently over time across the medications, with latanoprost leading to longer onset times compared to bimatoprost, although the data can't definitively imply cause and effect.
View Article and Find Full Text PDF

Background: Ocular metastasis (OM) is a rare metastatic site of primary liver cancer (PLC). The purpose of this study was to establish a clinical predictive model of OM in PLC patients based on machine learning (ML).

Methods: We retrospectively collected the clinical data of 1540 PLC patients and divided it into a training set and an internal test set in a 7:3 proportion.

View Article and Find Full Text PDF